NASDAQ:MACK

Merrimack Pharmaceuticals - MACK Stock Forecast, Price & News

$11.45

+0.04 (+0.35%)

(As of 01/27/2023 12:00 AM ET)

Add

Compare

Today's Range: $11.32
▼
$11.62
50-Day Range: $10.12
▼
$12.32
52-Week Range: $3.00
▼
$13.66

Volume: 115,376 shs
Average Volume: 234,546 shs
Market Capitalization: $153.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

About Merrimack Pharmaceuticals (NASDAQ:MACK) Stock

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Stock News Headlines

January 19, 2023 | americanbankingnews.com

Noah G. Levy Purchases 100,000 Shares of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Stock

December 13, 2022 | finance.yahoo.com

Bullish Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insiders filled their treasuries with US$574k worth of stock over last year

January 29, 2023 | Porter & Company (Ad)

Is This The End of Capitalism?

EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…

December 5, 2022 | finance.yahoo.com

Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan

November 16, 2022 | finance.yahoo.com

Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More

November 10, 2022 | finance.yahoo.com

Hedge funds investors control 44% of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) and were rewarded last week after stock increased 228%

November 9, 2022 | nasdaq.com

Merrimack Soars On Promising Data From Ipsen's NAPOLI-3 Trial

November 9, 2022 | finance.yahoo.com

Merrimack stock rockets 200% after positive trial data on Onivyde pancreatic cancer treatment

January 29, 2023 | Porter & Company (Ad)

Is This The End of Capitalism?

EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…

November 9, 2022 | marketwatch.com

Merrimack Pharmaceuticals Shares Soar Premarket on Ipsen Study Success >MACK

November 3, 2022 | finance.yahoo.com

Merrimack Reports Third Quarter 2022 Financial Results

October 31, 2022 | seekingalpha.com

Return Of The Mack: A Deeply Misunderstood Near-Term Readout

October 26, 2022 | marketwatch.com

Knee Bursitis Treatment Market Analysis Research Report, Challenges, Scopes, Market Share, Revenue, and Forecasts 2022 to 2028

October 17, 2022 | usatoday.com

Merrimack has 6 TDs in second half to run away from Wagner

September 2, 2022 | fool.com

Merrimack Pharmaceuticals (NASDAQ: MACK)

August 16, 2022 | finance.yahoo.com

Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth

August 8, 2022 | seekingalpha.com

Merrimack Pharmaceuticals: Out For Now

August 4, 2022 | marketwatch.com

Merrimack Pharma Shares Tumble Premarket After Ipsen's Onivyde Update >MACK

August 3, 2022 | nasdaq.com

Merrimack: Ipsen's Phase 3 Trial Of Onivyde Fails To Meet Primary Endpoint

August 3, 2022 | finance.yahoo.com

Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer

July 22, 2022 | nz.finance.yahoo.com

Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032: Visiongain Reports Ltd

July 6, 2022 | finance.yahoo.com

Bullish insiders at Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) loaded up on US$574k of stock earlier this year

May 5, 2022 | seekingalpha.com

Merrimack Pharmaceuticals GAAP EPS of -$0.01

March 16, 2022 | bizjournals.com

This drug manufactured in Lynnwood can help you survive a nuclear blast

March 16, 2022 | bizjournals.com

This Mass. company’s drug can help you survive a nuclear blast

March 9, 2022 | finance.yahoo.com

Merrimack Reports Full Year 2021 Financial Results

March 9, 2022 | seekingalpha.com

Merrimack Pharmaceuticals reports FY results

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Company Calendar

Last Earnings: 11/03/2022
Today: 1/29/2023
Next Earnings (Estimated): 3/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:MACK
CUSIP: 59032810
CIK: 1274792
Web: www.merrimackpharma.com
Phone: 617-720-8606
Fax: 617-491-1386
Employees: 426
Year Founded: 2000

Profitability

EPS (Most Recent Fiscal Year): ($0.11)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-2,450,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -14.32%
Return on Assets: -13.82%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 30.42
Quick Ratio: 30.42

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.06 per share
Price / Book: 10.80

Miscellaneous

Outstanding Shares: 13,410,000
Free Float: 9,950,000
Market Cap: $153.54 million
Optionable: Optionable
Beta: 1.88

Social Links

Key Executives

Mr. Gary L. Crocker M.B.A. (Age 70)
MBA, Pres, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
Comp: $105.44k

Dr. Ulrik B. Nielsen Ph.D. (Age 50)
Co-Founder & Independent Director
Comp: $102.76k

Dr. Anthony J. Sinskey Ph.D. (Age 82)
Sc.D., Co-Founder and Scientific Advisor

Geoffrey Grande C.F.A.
Sr. Director of Communications

Ms. Ellen K. Forest (Age 58)
Head of HR

Dr. Fazal R. Khan Ph.D. (Age 72)
Sr. VP of Manufacturing

Dr. Daryl C. Drummond Ph.D. (Age 53)
Head of Research

Mr. Timothy R. Surgenor (Age 62)
Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MACK Stock - Frequently Asked Questions

How have MACK shares performed in 2023?: Merrimack Pharmaceuticals' stock was trading at $11.46 on January 1st, 2023. Since then, MACK stock has decreased by 0.1% and is now trading at $11.45.
View the best growth stocks for 2023 here.
When is Merrimack Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our MACK earnings forecast.
How were Merrimack Pharmaceuticals' earnings last quarter?: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) released its quarterly earnings data on Thursday, November, 3rd. The biopharmaceutical company reported ($0.03) EPS for the quarter.
When did Merrimack Pharmaceuticals' stock split?: Merrimack Pharmaceuticals shares reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Merrimack Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).
What is Merrimack Pharmaceuticals' stock symbol?: Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."
How do I buy shares of Merrimack Pharmaceuticals?: Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Merrimack Pharmaceuticals' stock price today?: One share of MACK stock can currently be purchased for approximately $11.45.
How much money does Merrimack Pharmaceuticals make?: Merrimack Pharmaceuticals (NASDAQ:MACK) has a market capitalization of $153.54 million. The biopharmaceutical company earns $-2,450,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis.
How many employees does Merrimack Pharmaceuticals have?: The company employs 426 workers across the globe.
How can I contact Merrimack Pharmaceuticals?: Merrimack Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The official website for the company is www.merrimackpharma.com. The biopharmaceutical company can be reached via phone at 617-720-8606, via email at ir@merrimack.com, or via fax at 617-491-1386.

This page (NASDAQ:MACK) was last updated on 1/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial